Roche claims key win in the $12B early-stage checkpoint race
Roche has staked a toehold in the race to push checkpoint therapies into earlier and earlier stages of cancer.
The Swiss pharma announced Monday that, in a Phase III trial of early-stage lung cancer patients, those who received the PD-1 blocker Tecentriq lived longer without their disease returning than patients who received chemotherapy did. Known as IMpower010, the study looked at non-small cell lung cancer patients who had already undergone surgery to remove their tumor.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.